

Givaudan^o

ENGAGING
THE
SENSES



Good business momentum – currency and raw material headwinds

Half Year Results 2011

Vernier, 4 August 2011

Givaudan[®]

ENGAGING
THE
SENSES

Gilles Andrier

CEO


Half Year 2011 Results

- Good growth in line with mid-term targets
 - Full project pipeline and increased win rate
 - Strong innovation from R&D
- Raw materials further increased to 15% on a full year basis
- Price increases continue to be implemented
- Strong Swiss franc impacts financials


Givaudan's business momentum continues to be strong with a full project pipeline and a further increased win rate. The company is therefore confident to achieve its ambitious mid-term targets.

Half Year Sales 2011 Performance

In line with mid-term guidance



In million CHF





Sales Evolution by Market

(in million CHF)




HY 2010



HY 2011




Sales Evolution by Region (in million CHF)



Fragrance Division

Sales and Comparable EBITDA



Fine Fragrances decreased 0.4% in I.c.

- Latin America delivered strong growth driven by new wins and the existing products
- Sales of new wins in the mature markets were offset by the erosion, resulting in a decline overall

Consumer Products up 4.7% in I.c.


- Developing and mature markets contributed to this sales development
- Good growth in all segments, especially strong growth in fabric softeners due to new encapsulation systems

Fragrance Ingredients up 6.8% in I.c.

- Strong growth in specialties and commodities
- Paradisamide™, a long-lasting fresh tropical fruit note, was launched

Flavour Division

Sales and Comparable EBITDA



Double-digit growth in Health and Wellness taste solutions and continued strong growth in developing markets.

- Asia Pacific increased 9.6% in l.c. driven by China, India, Thailand, Australia and Japan.
- Europe, Africa and Middle East grew 4.1% in l.c., due to the strong growth in Eastern Europe and the Middle East.
- North America grew 3.4% in l.c. driven by Savoury, Snacks and Beverages.
- Latin American sales remained flat on the back of strong comparables. Beverages, Snacks and Sweet Goods performed best.

Continued Commitment to R&D

Strong innovation in all areas



- New captive molecule Karmaflor™, white flower with green tropical freshness
- Successfully developed Keratinoscent™, the first skin sensation in-vitro bio assay
- Further progress in controlled release systems
- Continued innovation in Health and Wellness taste solutions with the first commercialisation of high-performing synthetic sweetness enhancer.
- High throughput screening using proprietary receptor-based bio-assays allows to screen natural flavour enhancers
- Further progress in uniquely nuanced lemon and orange compositions inspired by the great array of citrus varieties of the University of California Riverside
- Improved chicken and beef flavours as a result of better understanding the interaction between umami and salt perception

Givaudan[®]

ENGAGING
THE
SENSES

Matthias Währen

CFO


Half Year 2011 Results

Financial Highlights

- Sales CHF 2 billion, up 4.3% in local currencies
- Comparable EBITDA decreased to CHF 382 million, due to raw material cost increases and currency translation effects
- Comparable EBITDA margin of 19.1%, affected by raw material cost increases
- Net income CHF 120 million
- Net debt of CHF 1.6 billion, leverage ratio at 33%.

Exchange Rates Development


Swiss Franc continues to strengthen against all major currencies



	JPY	USD	GBP	EUR		JPY	USD	GBP	EUR
HY 2011	1.10	0.90	1.46	1.27	30/06/2011	1.04	0.84	1.35	1.22
HY 2010	1.18	1.08	1.65	1.43	31/12/2010	1.15	0.93	1.46	1.25

Operating performance

Significantly impacted by raw material increases and CHF



- Sales of CHF 2,005 million (2010: CHF 2,199 million)
- Gross Margin of 43.0%, down from 46.8%, significantly impacted by surge in raw material costs
- Operating expenses remain under control
- Comparable EBITDA of CHF 382 million (2010 CHF 529 million), of which currency is CHF 43 million
- Comparable EBITDA margin of 19.1%, margins remain naturally protected against strong Swiss franc
- Operating Income of CHF 215 million (2010: CHF 330 million), given lower integration costs


Financing Costs and Other Financial Expenses

Under control, despite significant currency volatility

In Mio CHF

Financing Costs


Other Financial Expenses (net)



- Financing costs down in 2011, following conversion of MCS (lower interest and mandatory conversion feature)
- Other financial income and expenses – despite continued currency volatility, exposures remain limited, main losses from currencies which are expensive to hedge

Net Income

Significantly impacted by operating performance




- Income before tax of CHF 154 million, down from CHF 263 million in 2010, driven by:
 - Surge in raw material costs
 - Strong CHF
- Effective tax rate of 22% (2010: 24% at HY 2010)
- Net Income of CHF 120 million
- Basic EPS of CHF 13.19, versus CHF 22.58 in 2010

Free Cash Flow

Raw materials also impacting inventory levels


In Mio CHF



Future debt profile following July refinancing plan

Taking advantage of market conditions to refinance early


- July 2011: Refinancing of syndicated loan, new CHF 500 million facility negotiated
- Reimbursement of CHF 837 million short term debt from cash and initial draw down of CHF 250 million debt
- Additional draw down facilities available to refinance short term debt if required



Leverage Ratio

Underlying ratio trending to medium term target, but CTA impacting equity

- Leverage ratio of 33.0% at June 2011, up from Dec 2010 due primarily to dividend payment and CTA
- Expected cash generation in second six months will reduce leverage ratio in line with medium term target



Givaudan[®]

ENGAGING
THE
SENSES


Gilles Andrier

CEO

Short-term outlook

Improving second half 2011

- Lower comparables for Q3 and Q4
- Good progress on price pass through
- Continued strengthening of the Swiss franc
- Economic uncertainties remain
- Givaudan's business resilient



Medium-term Guidance

Profitable, above market growth

- Organic sales growth of 4.5% - 5.5% per year based on market growth of 2% - 3%
- Best-in-class EBITDA margins
- Free cash flow after capital investment and interest of 14% -16% of sales by 2015
- Return above 60% of the company's annual free cash flow to shareholders, after the leverage target reaches a level below 25% (leverage defined as net debt divided by net debt plus equity)

Well on Track Towards an Exciting Future

From number one to leadership

Unique platform for future growth in place

- Balanced portfolio across customers, geography, segments
- Critical mass and financial capability to invest into innovation
- In-depth global consumer understanding
- Best talent pool in the industry: unique and unrivalled innovation and creation capabilities
- Enhanced intimacy and close partnership with key accounts

Givaudan is well on track to further develop its leading position in the fragrance and flavour industry and deliver value to customers and shareholders.

Givaudan^e

ENGAGING
THE
SENSES

Disclaimer

No warranty and no liability: While Givaudan is making great efforts to include accurate and up-to-date information, we make no representations or warranties, expressed or implied, as to the accuracy or completeness of the information provided on this presentation/handout and disclaim any liability for the use of it.

No offer and no solicitation: The information provided on this handout does not constitute an offer of or solicitation for the purchase or disposal, trading or any transaction in any Givaudan securities. Investors must not rely on this information for investment decisions.

Forward-looking information: This handout may contain forward-looking information. Such information is subject to a variety of significant uncertainties, including scientific, business, economic and financial factors, and therefore actual results may differ significantly from those presented.

Copyright © 2011 Givaudan SA. All rights reserved.